1
|
Hoelzer D, Bassan R, Boissel N, Roddie C, Ribera JM, Jerkeman M. ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia. Ann Oncol 2024; 35:15-28. [PMID: 37832649 DOI: 10.1016/j.annonc.2023.09.3112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Revised: 09/14/2023] [Accepted: 09/25/2023] [Indexed: 10/15/2023] Open
Affiliation(s)
- D Hoelzer
- ONKOLOGIKUM Frankfurt am Museumsufer, Frankfurt, Germany
| | - R Bassan
- Hematology Unit, Ospedale dell'Angelo e Ospedale SS, Giovanni e Paolo, Mestre-Venezia, Italy
| | - N Boissel
- Hematology Department, Saint-Louis Hospital, APHP, Institut de Recherche Saint-Louis, Université de Paris Cité, Paris, France
| | - C Roddie
- Research Department of Haematology, UCL Cancer Institute, London, UK
| | - J M Ribera
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Jose Carreras Research Institute, Universitat Autonoma de Barcelona, Barcelona, Spain
| | - M Jerkeman
- Department of Oncology, Skåne University Hospital and Lund University, Lund, Sweden
| |
Collapse
|
2
|
Ekberg S, Harrysson S, Jernberg T, Szummer K, Andersson PO, Jerkeman M, Smedby KE, Eloranta S. Myocardial infarction in diffuse large B-cell lymphoma patients - a population-based matched cohort study. J Intern Med 2021; 290:1048-1060. [PMID: 34003533 DOI: 10.1111/joim.13303] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/15/2021] [Revised: 03/27/2021] [Accepted: 03/31/2021] [Indexed: 11/26/2022]
Abstract
BACKGROUND The outcome for diffuse large B-cell lymphoma (DLBCL) patients has improved with the immunochemotherapy combination R-CHOP. An increased rate of heart failure is well documented following this treatment, whereas incidence and outcome of other cardiac complications, for example myocardial infarction, are less well known. METHOD We identified 3548 curatively treated DLBCL patients in Sweden diagnosed between 2007 and 2014, and 35474 matched lymphoma-free general population comparators. The incidence, characteristics and outcome of acute myocardial infarctions (AMIs) were assessed using population-based registers up to 11 years after diagnosis. The rate of AMI was estimated using flexible parametric models. RESULTS Overall, a 33% excess rate of AMI was observed among DLBCL patients compared with the general population (HR: 1.33, 95% CI: 1.14-1.55). The excess rate was highest during the first year after diagnosis and diminished after 2 years. High age, male sex and comorbidity were the strongest risk factors for AMI. Older patients (>70 years) with mild comorbidities (i.e. hypertension or diabetes) had a 61% higher AMI rate than comparators (HR: 1.61, 95% CI: 1.10-2.35), whereas the corresponding excess rate was 28% for patients with severe comorbidities (HR: 1.28, 95% CI: 1.01-1.64). Among younger patients (≤70), a short-term excess rate of AMI was limited to those with severe comorbidities. There was no difference in AMI characteristics, pharmacological treatment or 30-day survival among patients and comparators. CONCLUSION DLBCL patients have an increased risk of AMI, especially during the first 2 years, which calls for improved cardiac monitoring guided by age and comorbidities. Importantly, DLBCL was not associated with differential AMI management or survival.
Collapse
Affiliation(s)
- S Ekberg
- From the, Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
| | - S Harrysson
- From the, Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.,Department of Hematology, Karolinska University Hospital, Solna, Sweden
| | - T Jernberg
- Department of Clinical Sciences, Danderyd University Hospital, Karolinska Institutet, Stockholm, Sweden
| | - K Szummer
- Section of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.,Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden
| | - P-O Andersson
- Department of Hematology, South Älvsborg Hospital, Borås, Sweden.,Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden
| | - M Jerkeman
- Division of Oncology, Lund University and Skane University Hospital, Lund, Sweden
| | - K E Smedby
- From the, Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.,Department of Hematology, Karolinska University Hospital, Solna, Sweden
| | - S Eloranta
- From the, Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
| |
Collapse
|
3
|
Meriranta L, Alkodsi A, Pasanen A, Lepistö M, Blaker YN, Jørgensen J, Mapar P, Björkholm M, Jerkeman M, Holte H, Pitkänen E, Ellonen P, Leppä S. HIGH RISK AGGRESSIVE B‐CELL LYMPHOMA ON THE LIQUID BIOPSY. Hematol Oncol 2021. [DOI: 10.1002/hon.4_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- L Meriranta
- University of Helsinki and Helsinki University Hospital Comprehensive Cancer Centre Department of Oncology and Applied Tumor Genomics Research Program Helsinki Finland
| | - A Alkodsi
- University of Helsinki and Helsinki University Hospital Comprehensive Cancer Centre Department of Oncology and Applied Tumor Genomics Research Program Helsinki Finland
| | - A Pasanen
- University of Helsinki and Helsinki University Hospital Comprehensive Cancer Centre Department of Oncology and Applied Tumor Genomics Research Program Helsinki Finland
| | - M Lepistö
- University of Helsinki Institute for Molecular Medicine Finland Helsinki Finland
| | - Y. N Blaker
- Oslo University Hospital Department of Oncology Oslo Norway
| | - J Jørgensen
- Aarhus University Hospital Department of Hematology Aarhus Denmark
| | - P Mapar
- University of Helsinki Institute for Molecular Medicine Finland HiLIFE & Applied Tumor Genomics Research Program Helsinki Finland
| | - M Björkholm
- Karoliska Institutet Department of Medicine Stockholm Sweden
| | - M Jerkeman
- Lund University Department of Oncology Lund Sweden
| | - H Holte
- Oslo University Hospital Department of Oncology Oslo Norway
| | - E Pitkänen
- University of Helsinki Institute for Molecular Medicine Finland HiLIFE & Applied Tumor Genomics Research Program Helsinki Finland
| | - P Ellonen
- University of Helsinki Institute for Molecular Medicine Finland Helsinki Finland
| | - S Leppä
- University of Helsinki and Helsinki University Hospital Comprehensive Cancer Centre Department of Oncology and Applied Tumor Genomics Research Program Helsinki Finland
| |
Collapse
|
4
|
Martelli M, Zucca E, Botto B, Kryachok I, Ceriani L, Balzarotti M, Tucci A, Cabras MG, Zilioli VR, Rusconi C, Angrilli F, Arcaini L, Iwanicka AD, Ferreri A, Merli F, Zhao W, Hodgson D, Ionescu C, Fosså A, Cwynarski K, Mikhaeel G, Jerkeman M, Janikova A, Hüttmann A, Ciccone G, Metser U, Barrington S, Malkowski B, Versari A, Esposito F, Cozens K, Ielmini N, Ricardi R, Cavalli F, Johnson P, Davies A. IMPACT OF DIFFERENT INDUCTION REGIMENS ON THE OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA IN THE PROSPECTIVE IELSG 37 TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.49_2879] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
5
|
Dreyling M, Ghielmini M, Rule S, Salles G, Ladetto M, Tonino SH, Herfarth K, Seymour JF, Jerkeman M. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021; 32:298-308. [PMID: 33249059 DOI: 10.1016/j.annonc.2020.11.008] [Citation(s) in RCA: 97] [Impact Index Per Article: 32.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2020] [Revised: 11/10/2020] [Accepted: 11/10/2020] [Indexed: 12/25/2022] Open
Affiliation(s)
- M Dreyling
- Department of Medicine III, LMU Hospital Munich, Germany
| | - M Ghielmini
- Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland
| | - S Rule
- Haematology, Peninsula School of Medicine, Plymouth, UK
| | - G Salles
- Service d'Hématologie, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon; Université Claude Bernard Lyon-1, Pierre-Benite, France
| | - M Ladetto
- Divisione di Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
| | - S H Tonino
- Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
| | - K Herfarth
- Department of Radiation Oncology, University of Heidelberg, Germany
| | - J F Seymour
- Department of Haematology, Peter McCallum Cancer Center & Royal Melbourne Hospital, Melbourne, University of Melbourne, Parkville, Australia
| | - M Jerkeman
- Department of Oncology, Skåne University Hospital, Lund University, Lund, Sweden
| |
Collapse
|
6
|
Lokhande L, Emruli V, Kolstad A, Hutchings M, Räty R, Rodrigues J, Jerkeman M, Ek S. SERUM BIOMARKERS ARE ASSOCIATED WITH TREATMENT RESPONSE IN RELAPSED MANTLE CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.72_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- L. Lokhande
- Department of Immunotechnology; Lund University; Lund Sweden
| | - V.K. Emruli
- Department of Immunotechnology; Lund University; Lund Sweden
| | - A. Kolstad
- Department of Oncology; Oslo University Hospital; Oslo Norway
| | - M. Hutchings
- Department of Haematology; Rigshospitalet; Copenhagen Copenhagen Denmark
| | - R. Räty
- Department of Hematology; Helsinki University Central Hospital; Helsinki Finland
| | - J.D. Rodrigues
- Department of Immunotechnology; Lund University; Lund Sweden
| | - M. Jerkeman
- Department of Oncology; Skane University Hospital; Lund Sweden
| | - S. Ek
- Department of Immunotechnology; Lund University; Lund Sweden
| |
Collapse
|
7
|
Karlsson I, Traub S, Järås K, Edwards D, Gramming E, Lindell Andersson M, To Y, Mårtensson L, Teige I, Acton G, Dyer M, Radford J, Collins G, Jerkeman M, Frendéus B, McAllister A, Davies A. PHASE 1/2A CLINICAL TRIALS OF BI-1206, A MONOCLONAL ANTIBODY TO FCΓRIIB, ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH RITUXIMAB IN SUBJECTS WITH B-CELL MALIGNANCIES. Hematol Oncol 2019. [DOI: 10.1002/hon.206_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- I. Karlsson
- Preclinical Research; BioInvent International AB; Lund Sweden
| | - S. Traub
- Centre for Drug Development; Cancer Research UK; London United Kingdom
| | - K. Järås
- Clinical Development; BioInvent International AB; Lund Sweden
| | - D. Edwards
- Centre for Drug Development; Cancer Research UK; London United Kingdom
| | - E. Gramming
- Clinical Development; BioInvent International AB; Lund Sweden
| | | | - Y. To
- Centre for Drug Development; Cancer Research UK; London United Kingdom
| | - L. Mårtensson
- Preclinical Research; BioInvent International AB; Lund Sweden
| | - I. Teige
- Preclinical Research; BioInvent International AB; Lund Sweden
| | - G. Acton
- Centre for Drug Development; Cancer Research UK; London United Kingdom
| | - M.J. Dyer
- Ernest and Helen Scott Haematological Research Institute; University of Leicester; Leicester United Kingdom
| | - J. Radford
- Institute of Cancer Sciences; University of Manchester; Manchester United Kingdom
| | - G.P. Collins
- Oxford Cancer and Haematology Centre; Churchill Hospital; Oxford United Kingdom
| | - M. Jerkeman
- Department of Oncology; Skane University Hospital; Lund Sweden
| | - B. Frendéus
- Preclinical Research; BioInvent International AB; Lund Sweden
| | - A. McAllister
- Clinical Development; BioInvent International AB; Lund Sweden
| | - A. Davies
- University of Southampton; Cancer Research UK Centre; Southampton United Kingdom
| |
Collapse
|
8
|
Leppä S, Jørgensen J, Tierens A, Meriranta L, Østlie I, Brown P, Fagerli U, Larsen T, Mannisto S, Munksgaard L, Maisenhølder M, Vasala K, Meyer P, Jerkeman M, Björkholm M, Fluge Ø, Jyrkkiö S, Ralfkiaer E, Spetalen S, Karjalainen-Lindsberg M, Holte H. YOUNG HIGH RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA INCLUDING BCL-2/MYC
DOUBLE HIT LYMPHOMAS BENEFIT FROM DOSE-DENSE IMMUNOCHEMOTHERAPY WITH EARLY CNS PROPHYLAXIS. Hematol Oncol 2019. [DOI: 10.1002/hon.92_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- S. Leppä
- Department of Oncology; Helsinki University Hospital Comprehensive Cancer Centre; Helsinki Finland
| | - J. Jørgensen
- Department of Hematology; Aarhus University Hospital; Aarhus Denmark
| | - A. Tierens
- Department of Pathology; University Health Network; Toronto Canada
| | - L. Meriranta
- Department of Oncology; Helsinki University Hospital Comprehensive Cancer Centre; Helsinki Finland
| | - I. Østlie
- Department of Pathology; Oslo University Hospital; Oslo Norway
| | - P. Brown
- Department of Hematology; Rigshospitalet; Copengahen Denmark
| | - U. Fagerli
- Department of Oncology; St. Olavs Hospital; Trondheim Norway
| | - T.S. Larsen
- Department of Hematology; Odense University Hospital; Odense Denmark
| | - S. Mannisto
- Department of Oncology; Helsinki University Hospital Comprehensive Cancer Centre; Helsinki Finland
| | - L. Munksgaard
- Department of Hematology; Roskilde Hospital; Roskilde Denmark
| | - M. Maisenhølder
- Department of Oncology; University Hospital of North Norway; Tromsø Norway
| | - K. Vasala
- Department of Oncology; Central Finland Central Hospital; Jyväskylä Finland
| | - P. Meyer
- Department of Oncology; Stavanger University Hospital; Stavanger Norway
| | - M. Jerkeman
- Department of Oncology; Skåne University Hospital; Lund Sweden
| | - M. Björkholm
- Department of Hematology; Karolinska University Hospital; Stockholm Sweden
| | - Ø. Fluge
- Department of Oncology; Haukeland University Hospital; Bergen Norway
| | - S. Jyrkkiö
- Department of Oncology; Turku University Hospital; Turku Finland
| | - E. Ralfkiaer
- Department of Pathology; Rigshospitalet; Copenhagen Denmark
| | - S. Spetalen
- Department of Pathology; Oslo University Hospital; Oslo Norway
| | | | - H. Holte
- Department of Oncology; Oslo University Hospital; Oslo Norway
| |
Collapse
|
9
|
Rodrigues J, Freiburghaus C, Carlsson A, Husby S, Eskelund C, Lokhande L, Kolstad A, Grønbaek K, Jerkeman M, Ek S. THE IMMUNE MICROENVIRONMENT AS A PROGNOSTIC TOOL FOR MCL PATIENTS. Hematol Oncol 2019. [DOI: 10.1002/hon.6_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- J.M. Rodrigues
- Department of Immunotechnology; Lund University; Lund Sweden
| | - C. Freiburghaus
- Department of Immunotechnology; Lund University; Lund Sweden
| | | | - S. Husby
- Department of Haematology; Rigshospitalet; Copenhagen Denmark
| | - C.W. Eskelund
- Department of Haematology; Rigshospitalet; Copenhagen Denmark
| | - L. Lokhande
- Department of Immunotechnology; Lund University; Lund Sweden
| | - A. Kolstad
- Department of Oncology; Division of Cancer Medicine, Oslo University Hospital; Oslo Norway
| | - K. Grønbaek
- Department of Haematology; Rigshospitalet; Copenhagen Denmark
| | - M. Jerkeman
- Department of Oncology; Lund University; Lund Sweden
| | - S. Ek
- Department of Immunotechnology; Lund University; Lund Sweden
| |
Collapse
|
10
|
Eskelund C, Kolstad A, Glimelius I, Räty R, Gjerdrum L, Sonnevi K, Josefsson P, Nilsson-Ehle H, Bentzen H, Fagerli U, Kuittinen O, Haaber J, Pedersen L, Larsen M, Geisler C, Hutchings M, Jerkeman M, Grønbaek K. EARLY PROGRESSION OF MANTLE CELL LYMPHOMA DEPICTS A HIGH-RISK DISEASE WITH POOR RESPONSE TO SUBSEQUENT THERAPIES AND A DISMAL OUTCOME. Hematol Oncol 2019. [DOI: 10.1002/hon.52_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- C.W. Eskelund
- Dept of Hematology; Rigshospitalet; Copenhagen O Denmark
| | - A. Kolstad
- Dept of Oncology; Oslo University Hospital; Oslo Norway
| | - I. Glimelius
- Dept of Oncology; Uppsala University and Uppsala Akademiska Hospital; Uppsala Sweden
| | - R. Räty
- Dept of Hematology; Helsinki University Hospital; Helsinki Finland
| | - L.R. Gjerdrum
- Dept of Pathology; Zealand University Hospital; Roskilde Denmark
| | - K. Sonnevi
- Dept of Hematology; Karolinska University Hospital; Stockholm Sweden
| | - P. Josefsson
- Dept of Hematology; Herlev Hospital; Herlev Denmark
| | - H. Nilsson-Ehle
- Dept of Hematology; Sahlgrenska University Hospital; Göteborg Sweden
| | - H. Bentzen
- Dept of Hematology; Aarhus University Hospital; Aarhus Denmark
| | - U. Fagerli
- Dept of Oncology; St. Olav's Hospital; Trondheim Norway
| | - O. Kuittinen
- Dept of Oncology; Kuopio University Hospital; Kuopio Finland
| | - J. Haaber
- Dept of Hematology; Odense University Hospital; Odense Denmark
| | - L.B. Pedersen
- Dept of Hematology; Rigshospitalet; Copenhagen O Denmark
| | - M.T. Larsen
- Dept of Hematology; Rigshospitalet; Copenhagen O Denmark
| | - C.H. Geisler
- Dept of Hematology; Rigshospitalet; Copenhagen O Denmark
| | - M. Hutchings
- Dept of Hematology; Rigshospitalet; Copenhagen O Denmark
| | - M. Jerkeman
- Dept of Oncology; Lund University Hospital; Lund Sweden
| | - K. Grønbaek
- Dept of Hematology; Rigshospitalet; Copenhagen O Denmark
| |
Collapse
|
11
|
Husby S, Eskelund C, Favero F, Rodriguez-Gonzalez F, Kolstad A, Pedersen L, Räty R, Geisler C, Jerkeman M, Weischenfeldt J, Grønbaek K. EVOLUTION OF CLONAL HEMATOPOIESIS IN MANTLE CELL LYMPHOMA PATIENTS BEFORE, DURING, AND AFTER INDUCTION CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION. Hematol Oncol 2019. [DOI: 10.1002/hon.50_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- S. Husby
- Dept. of Hematology; Rigshospitalet; Copenhagen N Denmark
| | - C.W. Eskelund
- Dept. of Hematology; Rigshospitalet; Copenhagen N Denmark
| | - F. Favero
- Biotech Research & Innovation Center (BRIC); University of Copenhagen; Copenhagen N Denmark
| | | | - A. Kolstad
- Dept. of Oncology; Oslo University Hospital; Oslo Norway
| | - L.B. Pedersen
- Dept. of Hematology; Rigshospitalet; Copenhagen N Denmark
| | - R. Räty
- Dept. of Hematology; Helsinki University Hospital; Helsinki Finland
| | - C.H. Geisler
- Dept. of Hematology; Rigshospitalet; Copenhagen N Denmark
| | - M. Jerkeman
- Dept. of Oncology; Lund University Hospital; Lund Sweden
| | - J. Weischenfeldt
- Biotech Research & Innovation Center (BRIC); University of Copenhagen; Copenhagen N Denmark
| | - K. Grønbaek
- Dept. of Hematology; Rigshospitalet; Copenhagen N Denmark
| |
Collapse
|
12
|
Wästerlid T, Mohammadi M, Smedby KE, Glimelius I, Jerkeman M, Bottai M, Eloranta S. Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma: a Swedish lymphoma register study. J Intern Med 2019; 285:455-468. [PMID: 30368947 DOI: 10.1111/joim.12849] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND Comorbidity impacts overall survival amongst patients with diffuse large B-cell lymphoma (DLBCL). However, associations of comorbidity with lymphoma characteristics, treatment selection and lymphoma-specific mortality are less well known. OBJECTIVE To examine the impact of comorbidity on DLBCL characteristics, treatment intent and cause of death. METHODS We identified 3905 adult patients diagnosed with DLBCL 2007-2013 through the Swedish Lymphoma Register. We assessed comorbid disease history according to the Charlson comorbidity index (CCI). Comorbidity data and causes of death were collected through register linkage. Associations were estimated using multinomial regression and flexible parametric survival models. RESULTS Overall, 45% of the patients (n = 1737) had a history of at least one comorbidity at DLBCL diagnosis (cardiovascular disease, diabetes and solid cancer were most frequent), and 997 (26%) had a CCI score of ≥2. The relative probability of presenting with poor performance status (PS > 2) was higher amongst comorbid patients [Relative Risk Ratio (RRR)PS>2 : 2.02, 95% CI: 1.63-2.51]. Comorbid patients had a substantially lower relative probability of receiving curative treatment (RRR: 0.48, 95% CI: 0.38-0.61). Amongst all patients, CCI ≥ 1 was associated with a significantly increased risk of all-cause and lymphoma-specific death after adjustments. Amongst patients selected for curative treatment, comorbidity was associated with an increased risk of all-cause death (HRCCI>1 : 1.54, 95% CI: 1.32-1.80), but not with lymphoma-specific death (HRCCI>1 : 1.05, 95% CI: 0.86-1.28). CONCLUSION Comorbidity is associated with inferior DLBCL outcome, mainly due to a lower likelihood of receiving treatment with curative intent. Possibly, more comorbid DLBCL patients could be treated with curative intent if comorbid conditions were optimized in parallel.
Collapse
Affiliation(s)
- T Wästerlid
- Department of Medicine Solna, Division of Clinical Epidemiology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.,Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
| | - M Mohammadi
- Institute of Environmental Medicine, Division of Epidemiology, Karolinska Institutet, Stockholm, Sweden
| | - K E Smedby
- Department of Medicine Solna, Division of Clinical Epidemiology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.,Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
| | - I Glimelius
- Department of Medicine Solna, Division of Clinical Epidemiology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.,Department of Immunology, Genetics and Pathology, Unit of Oncology, Uppsala University, Uppsala, Sweden
| | - M Jerkeman
- Department of Oncology, Lund University Hospital, Lund, Sweden
| | - M Bottai
- Institute of Environmental Medicine, Division of Epidemiology, Karolinska Institutet, Stockholm, Sweden
| | - S Eloranta
- Department of Medicine Solna, Division of Clinical Epidemiology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
| |
Collapse
|
13
|
Rule S, Jurczak W, Jerkeman M, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Thieblemont C, Zhou W, Henninger T, Goldberg J, Vermeulen J, Dreyling M. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia 2018; 32:1799-1803. [PMID: 29572505 PMCID: PMC6087720 DOI: 10.1038/s41375-018-0023-2] [Citation(s) in RCA: 63] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2017] [Revised: 11/21/2017] [Accepted: 12/22/2017] [Indexed: 11/23/2022]
Affiliation(s)
- S Rule
- Plymouth University Medical School, Plymouth, UK.
| | - W Jurczak
- Department of Hematology, Jagiellonian University, Krakow, Poland
| | - M Jerkeman
- Skånes University Hospital, Lund University, Lund, Sweden
| | - C Rusconi
- Hematology Division, Hematology and Oncology Department, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy
| | - M Trneny
- Ist Dept Medicine, Charles University General Hospital, Prague, Czech Republic
| | - F Offner
- Departement Oncologie, UZ Gent, Ghent, Belgium
| | - D Caballero
- Instituto Biosanitario de Salamanca, Hospital Clinico Universitario Salamanca, Salamanca, Spain
| | - C Joao
- Institutto Português de Oncologia de Lisboa, Portugal and Champalimaud Centre for the Unknown, Hematology, Lisbon, Portugal
| | - M Witzens-Harig
- Klinikum der Ruprechts-Karls-Universität Heidelberg, Med. Klinik u. Poliklinik V, Heidelberg, Germany
| | - G Hess
- Department of Hematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University, Mainz, Germany
| | | | - S-G Cho
- Seoul St. Mary's Hospital, Seocho-gu, Seoul, South Korea
| | - C Thieblemont
- APHP, Saint-Louis Hospital, Hemato-oncology, Diderot University, Paris, France
| | - W Zhou
- Janssen Research & Development, Raritan, NJ, USA
| | - T Henninger
- Janssen Research & Development, Raritan, NJ, USA
| | - J Goldberg
- Janssen Research & Development, Raritan, NJ, USA
| | - J Vermeulen
- Janssen Research & Development, Leiden, The Netherlands
| | - M Dreyling
- Department of Medicine III, Klinikum der Universität München, LMU, Munich, Germany
| |
Collapse
|
14
|
Wästerlid T, Biccler J, Brown P, Bøgsted M, Enblad G, Mészáros Jørgensen J, Christensen J, Wahlin B, Smedby K, El-Galaly T, Jerkeman M. Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study. Ann Oncol 2018; 29:1882-1883. [DOI: 10.1093/annonc/mdy184] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
|
15
|
Abstract
Pharmacological agents that inhibit enzymes of the B-cell receptor (BCR) pathway are of increasing importance in the treatment of B-cell malignancies. These include inhibitors of Bruton tyrosine kinase (BTK), phosphatidylinositol 3-kinase (PI3K), splenic tyrosine kinase and protein kinase Cβ. Two agents are already approved in the USA and Europe: ibrutinib, a BTK inhibitor, for the treatment of chronic lymphatic leukaemia (CLL), mantle cell lymphoma (MCL) and Waldenström's macroglobulinemia; and idelalisib, a PI3Kδ inhibitor, for the treatment of CLL and follicular lymphoma. In addition, the role of these drugs in diffuse large B-cell lymphoma and marginal zone lymphoma is under investigation, as single agents and in combination with chemotherapy. In CLL, both ibrutinib and idelalisib have an established role as first-line therapy in patients with del(17p), and in MCL, ibrutinib is a standard option for patients relapsing after chemoimmunotherapy. Unexpected toxicities have been encountered when combining these potent new agents with other drugs, including chemotherapy and lenalidomide, and based on this experience the risks and benefits of novel combinations must be evaluated carefully. In this review, we summarize the efficacy and safety results with these inhibitors and discuss novel combinations that are under study and the future role of BCR inhibitors in these disorders.
Collapse
Affiliation(s)
- M Jerkeman
- Department of Oncology, Lund University, Lund, Sweden
| | - M Hallek
- Department of Internal Medicine I, Cologne University Hospital, Cologne, Germany
| | - M Dreyling
- Department of Medicine III, University of Munich, Munich, Germany
| | - C Thieblemont
- Hemato-Oncology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - E Kimby
- Hematology Center, Department of Medicine, Karolinska Institute, Stockholm, Sweden
| | - L Staudt
- Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| |
Collapse
|
16
|
Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, Shpilberg O, Walewski J, Ladetto M. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28:iv62-iv71. [PMID: 28881919 DOI: 10.1093/annonc/mdx223] [Citation(s) in RCA: 176] [Impact Index Per Article: 25.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Affiliation(s)
- M Dreyling
- Department of Medicine III, University Hospital - LMU Munich, Munich, Germany
| | - E Campo
- Hematopathology Section, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
| | - O Hermine
- Department of Hematology, Imagine Institute and Descartes University, INSERM U1163 and CNRS ERL 8564, Necker Hospital, Paris, France
| | - M Jerkeman
- Department of Hematology, University Lund, Lund, Sweden
| | - S Le Gouill
- CHU de Nantes, Service d'Hématologie Clinique, Université de Nantes, Nantes, France
| | - S Rule
- Peninsula School of Medicine and Dentistry, University of Plymouth, Plymouth, UK
| | - O Shpilberg
- Institute of Hematology, Assuta Medical Center, Tel-Aviv, Israel
| | - J Walewski
- Department of Lymphoid Malignancy, Maria Sklodowska-Curie Institute and Oncology Centre, Warsaw, Poland
| | - M Ladetto
- Divisione di Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
| |
Collapse
|
17
|
Rule S, Jurczak W, Jerkeman M, Santucci Silva R, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho S, Thieblemont C, Zhou W, Henninger T, Goldberg J, Vermeulen J, Dreyling M. IBRUTINIB VS TEMSIROLIMUS: THREE-YEAR FOLLOW-UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN-LABEL RAY STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_133] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- S. Rule
- Haematology; Derriford Hospital; Plymouth UK
| | - W. Jurczak
- Hematology; Jagiellonian University; Krakow Poland
| | - M. Jerkeman
- Oncology; Skånes University Hospital; Lund Sweden
| | - R. Santucci Silva
- Oncology; Instituto de Ensino e Pesquisa Sao Lucas; Sao Paulo Brazil
| | - C. Rusconi
- Hematology and Oncology; Niguarda Hospital; Milan Italy
| | - M. Trneny
- First Department Medicine; Charles University General Hospital; Prague Czech Republic
| | | | - D. Caballero
- Hematology; Hospital Clinico Universitario Salamanca; Salamanca Spain
| | - C. Joao
- Oncology; Institutto Português de Oncologia de Lisboa; Lisbon Portugal
| | | | - G. Hess
- Hematology, Oncology and Pneumology; University Medical School of the Johannes Gutenberg University; Mainz Germany
| | | | - S. Cho
- Hematology; Seoul St. Mary's Hospital; Seoul Republic of Korea
| | | | - W. Zhou
- Oncology; Janssen Research & Development; Raritan USA
| | - T. Henninger
- Oncology; Janssen Research & Development; Raritan USA
| | - J.D. Goldberg
- Oncology; Janssen Research & Development; Raritan USA
| | - J. Vermeulen
- Oncology; Janssen Research & Development; Beerse Belgium
| | - M. Dreyling
- Medicine III; Klinikum der Universität München, LMU; Munich Germany
| |
Collapse
|
18
|
Smedby K, Ekberg S, Andersson P, Enblad G, Wahlin B, Hasselblom S, Jerkeman M, Eloranta S. LONG-TERM SURVIVAL AND LOSS IN EXPECTANCY OF LIFE IN A POPULATION-BASED COHORT OF 7114 PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- K.E. Smedby
- Dept of Medicine Solna; Karolinska Institutet; Solna Sweden
| | - S. Ekberg
- Dept of Medicine Solna; Karolinska Institutet; Solna Sweden
| | - P. Andersson
- Dept of Medicine; Unit of Hematology; Borås Sweden
| | - G. Enblad
- Dept of Oncology, Genetics and Pathology, Unit of Oncology; Uppsala Sweden
| | - B.E. Wahlin
- Dept of Medicine Huddinge; Div of Hematology; Huddinge Sweden
| | - S. Hasselblom
- Dept of Research; Development & Education, Unit of Research in Hematology; Halmstad Sweden
| | - M. Jerkeman
- Dept of Oncology and Pathology; Institute of Clinical Sciences; Lund Sweden
| | - S. Eloranta
- Dept of Medicine Solna; Karolinska Institutet; Solna Sweden
| |
Collapse
|
19
|
Freiburghaus C, Kuci Emruli V, Johansson A, Olsson R, Ek F, Geisler C, Jerkeman M, Ek S. BORTEZOMIB PREVENTS DEVELOPMENT OF CYTARABINE RESISTANCE IN A MANTLE CELL LYMPHOMA IN VITRO
MODEL. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- C. Freiburghaus
- Department of Immunotechnology; Lund University; Lund Sweden
| | - V. Kuci Emruli
- Department of Immunotechnology; Lund University; Lund Sweden
| | - A. Johansson
- Department of Immunotechnology; Lund University; Lund Sweden
| | - R. Olsson
- Department of Experimental Medical Science; Lund University; Lund Sweden
| | - F. Ek
- Department of Experimental Medical Science; Lund University; Lund Sweden
| | - C.H. Geisler
- Department of Hematology; Copenhagen University Hospital, Rigshospitalet; Copenhagen Denmark
| | - M. Jerkeman
- Department of Oncology; Skåne University Hospital; Lund Sweden
| | - S. Ek
- Department of Immunotechnology; Lund University; Lund Sweden
| |
Collapse
|
20
|
Biccler J, Glimelius I, Eloranta S, de Nully Brown P, Jakobsen L, Frederiksen H, Jerkeman M, Bøgsted M. MORTALITY RATES REMAIN INCREASED IN YOUNG PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA EVEN AFTER YEARS IN REMISSION: RESULTS FROM A NORDIC LYMPHOMA GROUP STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- J. Biccler
- Department of Hematology; Aalborg University Hospital; Aalborg Denmark
| | - I. Glimelius
- Unit of Clinical Epidemiology; Institute of Medicine Solna,, Karolinska Institutet; Stockholm Sweden
| | - S. Eloranta
- Unit of Clinical Epidemiology; Institute of Medicine Solna,, Karolinska Institutet; Stockholm Sweden
| | - P. de Nully Brown
- Department of Hematology; Copenhagen University Hospital, Rigshospitalet; Copenhagen Ø Denmark
| | - L.H. Jakobsen
- Department of Clinical Medicine; Aalborg University; Aalborg Denmark
| | - H. Frederiksen
- Department of Hematology; Odense University Hospital; Odense Denmark
| | - M. Jerkeman
- Department of Clinical Sciences; Lund University; Lund Sweden
| | - M. Bøgsted
- Department of Clinical Medicine; Aalborg University; Aalborg Denmark
| |
Collapse
|
21
|
Morello L, Rattotti S, Jerkeman M, van Meerten T, Krawczyk K, Moita F, Marino D, Ferrero S, Szymczyk M, Aurer I, El-Galaly T, Di Rocco A, Carli G, Defrancesco I, Giordano L, Carlo-Stella C, Dreyling M, Santoro A, Arcaini L. MANTLE CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE: A RETROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF THE EUROPEAN MANTLE CELL LYMPHOMA NETWORK. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_66] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- L. Morello
- Department of Oncology and Hematology; Humanitas Clinical and Research Center, Rozzano, Italy; Rozzano (MI) Italy
| | - S. Rattotti
- Department of Hematology and Oncology, Fondazione IRCCS Policlinico S. Matteo; University of Pavia, Italy; Pavia Italy
| | - M. Jerkeman
- Department of Oncology; Skane University Hospital; Lund Sweden
| | - T. van Meerten
- Department of Hematology; University Medical Center Groningen; Groningen The Netherlands
| | - K. Krawczyk
- Department of Hematology; Jagiellonian University; Krakow Poland
| | - F. Moita
- Instituto Português de Oncologia de Lisboa, Francisco Gentil; Lisbon Portugal
| | - D. Marino
- Oncology Unit 1; Veneto Institute of Oncology IOV-IRCCS; Padova Italy
| | - S. Ferrero
- Division of Hematology, Department of Molecular Biotechnologies and Health Sciences; University of Torino; Torino Italy
| | - M. Szymczyk
- Department of Lymphoid Malignancies, The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology; Warsaw Poland
| | - I. Aurer
- Division of Hematology, Department of Internal Medicine; University Hospital Centre Zagreb; Zagreb Croatia
| | - T.C. El-Galaly
- Department of Hematology; Aalborg University Hospital; Aalborg Denmark
| | - A. Di Rocco
- Department of Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - G. Carli
- Department of Cell Therapy and Haematology; San Bortolo Hospital; Vicenza Italy
| | - I. Defrancesco
- Department of Hematology and Oncology, Fondazione IRCCS Policlinico S. Matteo; University of Pavia, Italy; Pavia Italy
| | - L. Giordano
- Department of Oncology and Hematology; Humanitas Clinical and Research Center, Rozzano, Italy; Rozzano (MI) Italy
| | - C. Carlo-Stella
- Department of Oncology and Hematology; Humanitas Clinical and Research Center, Rozzano, Italy; Rozzano (MI) Italy
| | - M. Dreyling
- Department of Internal Medicine III; Ludwig-Maximilians University Hospital Munich; Munchen Germany
| | - A. Santoro
- Department of Oncology and Hematology; Humanitas Clinical and Research Center, Rozzano, Italy; Rozzano (MI) Italy
| | - L. Arcaini
- Department of Hematology and Oncology, Fondazione IRCCS Policlinico S. Matteo; University of Pavia, Italy; Pavia Italy
| |
Collapse
|
22
|
Leppä S, Joergensen J, de Nully Brown P, Fagerli U, Larsen T, Janes R, Mannisto S, Munksgaard L, Maisenhölder M, Vasala K, Meyer P, Jerkeman M, Björkholm M, Fluge Ø, Jyrkkiö S, Pedersen L, Eriksson M, Holte H. DOSE-DENSE CHEMOIMMUNOTHERAPY AND CNS PROPHYLAXIS IN PATIENTS WITH HIGH-RISK DLBCL: A COMPARISON OF NORDIC CRY-04 AND CHIC STUDIES. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_62] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- S. Leppä
- Department of Oncology; Helsinki University Hospital Cancer Center; Helsinki Finland
| | - J. Joergensen
- Department of Haematology; Aarhus University Hospital; Aarhus Denmark
| | | | - U. Fagerli
- Department of Oncology; St. Olavs Hospital HF; Trondheim Norway
| | - T.S. Larsen
- Department of Haematology; Odense University Hospital; Odense Denmark
| | - R. Janes
- Department of Oncology; Helsinki University Hospital Cancer Center; Helsinki Finland
| | - S. Mannisto
- Department of Oncology; Helsinki University Hospital Cancer Center; Helsinki Finland
| | - L. Munksgaard
- Department of Haematology; Roskilde Hospital; Roskilde Denmark
| | - M. Maisenhölder
- Department of Oncology; University Hospital of North Norway; Tromsö Norway
| | - K. Vasala
- Department of Oncology, Central Finland Central Hospital; Jyväskylä Finland
| | - P. Meyer
- Department of Hematology and Oncology; Stavanger University Hospital; Stavanger Norway
| | - M. Jerkeman
- Department of Oncology; Skane University Hospital; Lund Sweden
| | - M. Björkholm
- Department of Medicine; Karolinska University Hospital; Stockholm Sweden
| | - Ø. Fluge
- Department of Oncology; Haukeland University Hospital; Bergen Norway
| | - S. Jyrkkiö
- Department of Oncology; Turku University Hospital; Turku Finland
| | - L.M. Pedersen
- Department of Haematology; Herlev Hospital; Herlev Denmark
| | - M. Eriksson
- Department of Oncology; Skane University Hospital; Lund Sweden
| | - H. Holte
- Department of Oncology; Oslo University Hospital; Oslo Norway
| |
Collapse
|
23
|
Biccler J, Eloranta S, de Nully Brown P, Frederiksen H, Jerkeman M, Smedby K, Bøgsted M, El-Galaly T. OUTCOME PREDICTION IN DIFFUSE LARGE B-CELL LYMPHOMA CAN BE GREATLY IMPROVED BY ALTERNATIVE USE OF CLINICAL INFORMATION: A NORDIC LYMPHOMA GROUP STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_40] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- J.L. Biccler
- Department of Hematology; Aalborg University Hospital; Aalborg Denmark
| | - S. Eloranta
- Unit of Clinical Epidemiology, Institute of Medicine Solna; Karolinska Institute; Stockholm Sweden
| | - P. de Nully Brown
- Department of Hematology; Copenhagen University Hospital, Rigshospitalet; Copenhagen Ø Denmark
| | - H. Frederiksen
- Department of Hematology; Odense University Hospital; Odense Denmark
| | - M. Jerkeman
- Department of Clinical Sciences; Lund University; Lund Sweden
| | - K.E. Smedby
- Department of Medicine; Karolinska Institute; Solna Sweden
| | - M. Bøgsted
- Department of Clinical Medicine; Aalborg University Hospital; Aalborg Denmark
| | - T.C. El-Galaly
- Department of Hematology; Aalborg University Hospital; Aalborg Denmark
| |
Collapse
|
24
|
Pauly F, Fjordén K, Leppä S, Holte H, Björkholm M, Fluge Ø, Møller Pedersen L, Eriksson M, Isinger-Ekstrand A, Borrebaeck CAK, Jerkeman M, Wingren C. Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study. Blood Cancer J 2016; 6:e501. [PMID: 27858932 PMCID: PMC5148057 DOI: 10.1038/bcj.2016.113] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Affiliation(s)
- F Pauly
- Department of Immunotechnology, Lund University, Lund, Sweden.,CREATE Health, Lund University, Lund, Sweden
| | - K Fjordén
- Department of Oncology, Lund University, Skåne University Hospital, Lund, Sweden
| | - S Leppä
- Department of Oncology, Helsinki University Hospital, Helsinki, Finland
| | - H Holte
- Department of Oncology, Oslo University Hospital, Oslo, Norway
| | - M Björkholm
- Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
| | - Ø Fluge
- Department of Oncology, Haukeland University Hospital, Bergen, Norway
| | | | - M Eriksson
- Department of Oncology, Lund University, Skåne University Hospital, Lund, Sweden
| | - A Isinger-Ekstrand
- Department of Immunotechnology, Lund University, Lund, Sweden.,CREATE Health, Lund University, Lund, Sweden
| | - C A K Borrebaeck
- Department of Immunotechnology, Lund University, Lund, Sweden.,CREATE Health, Lund University, Lund, Sweden
| | - M Jerkeman
- Department of Oncology, Lund University, Skåne University Hospital, Lund, Sweden
| | - C Wingren
- Department of Immunotechnology, Lund University, Lund, Sweden.,CREATE Health, Lund University, Lund, Sweden
| |
Collapse
|
25
|
Glimelius I, Ekberg S, Linderoth J, Jerkeman M, Chang ET, Neovius M, Smedby KE. Erratum to: Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time-a population-based comparative study. J Cancer Surviv 2016; 9:610-1. [PMID: 26130293 DOI: 10.1007/s11764-015-0464-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- I Glimelius
- Section of Oncology, Department of Immunology, Genetics and Pathology, University of Uppsala, Uppsala, Sweden
- Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
| | - S Ekberg
- Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
| | - J Linderoth
- Department of Oncology, Skåne University Hospital, Lund, Sweden
| | - M Jerkeman
- Department of Oncology, Skåne University Hospital, Lund, Sweden
| | - E T Chang
- Health Sciences Practice, Exponent, Inc., Menlo Park, CA, USA
- Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA, USA
| | - M Neovius
- Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
| | - K E Smedby
- Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
| |
Collapse
|
26
|
Glimelius I, Ekberg S, Linderoth J, Jerkeman M, Chang ET, Neovius M, Smedby KE. Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time—a population-based comparative study. J Cancer Surviv 2015; 9:599-609. [DOI: 10.1007/s11764-015-0436-0] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2014] [Accepted: 01/27/2015] [Indexed: 10/24/2022]
|
27
|
Wästerlid T, Brown PN, Hagberg O, Hagberg H, Pedersen LM, D'Amore F, Jerkeman M. Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. Ann Oncol 2013; 24:1879-1886. [PMID: 23446093 DOI: 10.1093/annonc/mdt058] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Standard treatment of adult Burkitt lymphoma is not defined due to the lack of randomised trials. In this situation, population-based data may represent a useful contribution in order to identify an optimal treatment strategy. PATIENTS AND METHODS The aims of this study were to investigate the outcome for adult HIV-negative BL with different chemotherapy regimens, and to assess possible improvement within the time frame of the study. The study population was identified through the Swedish and Danish lymphoma registries 2000-2009. RESULTS A total of 258 patients were identified. Since 2000, overall survival (OS) improved significantly only for younger patients (<65 years). Intensive regimens such as the Berlin-Frankfurt-Münster, hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) and cyclophosphamide, vincristine, doxorubicin, methotrexate, ifosfamide, etoposide, and cytarabine (CODOX-M/IVAC) were associated with a favourable 2-year OS of 82%, 83%, and 69%, respectively. The low-intensive CHOP/CHOEP regimens achieved a 2-year OS of 38.8%, confirming their inadequacy for the treatment of BL. In a multivariate analysis, rituximab was not significantly associated with improved OS. CONCLUSIONS In this population-based retrospective series of adult BL, intensive chemotherapy regimens were associated with favourable outcome. The impact of the addition of rituximab remains uncertain and warrants further investigation.
Collapse
Affiliation(s)
- T Wästerlid
- Department of Oncology, Skåne University Hospital, Lund, Sweden
| | - P N Brown
- Department of Haematology, Rigshospitalet, Copenhagen, Denmark
| | - O Hagberg
- Department of Tumour Epidemiology, Skåne University Hospital, Lund
| | - H Hagberg
- Department of Oncology, Akademiska University Hospital, Uppsala, Sweden
| | - L M Pedersen
- Department of Haematology, Roskilde Hospital, Roskilde
| | - F D'Amore
- Department of Haematology, Århus University Hospital, Århus, Denmark
| | - M Jerkeman
- Department of Oncology, Skåne University Hospital, Lund, Sweden.
| |
Collapse
|
28
|
Holte H, Leppä S, Björkholm M, Fluge Ø, Jyrkkiö S, Delabie J, Sundström C, Karjalainen-Lindsberg ML, Erlanson M, Kolstad A, Fosså A, Østenstad B, Löfvenberg E, Nordström M, Janes R, Pedersen L, Anderson H, Jerkeman M, Eriksson M. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol 2013; 24:1385-92. [DOI: 10.1093/annonc/mds621] [Citation(s) in RCA: 88] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
29
|
Nordström L, Andréasson U, Jerkeman M, Dictor M, Borrebaeck C, Ek S. 763 Expanded Clinical and Experimental Use of SOX11 – Using a Monoclonal Antibody. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71399-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
30
|
Holte H, Bogsrud T, Leppa S, Laukka M, Bjorkholm M, Jacobsson H, Jyrkkio S, Seppanen M, Jerkeman M, Brun E, Fluge O, Pedersen LM, Eriksson M. 18FDG PET/CT after intensified chemo-immunotherapy in diffuse large B-cell lymphoma (DLBCL), aged 18-65 with aaIPI 2-3 positive or indeterminate lesions are often false-positive: A Nordic phase II substudy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e18519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
31
|
Geisler C, Kolstad A, Laurell A, Räty R, Jerkeman M, Eriksson M, Nordström M, Kimby E, Bentzen H, Nilsson-Ehle H, Kuittinen O, Lauritzsen G, Ralfkiær E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Pedersen L, Andersen N, Brown P, Elonen E. Nordic MCL2 Trial of 1St-Line Intensive Immunochemotherapy and Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: Still Encouraging Results After Median 5½ Years Observation Time. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.138] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
32
|
Jerkeman M, Kolstad A, Laurell A, Räty R, Gr∅nbæk K, Geisler C. Lenalidomide, bendamustine, and rituximab as first-line therapy for patients > 65 years with mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) trial. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
33
|
Olofsson S, Dahl O, Jerkeman M, Cohn-Cedermark G, Klepp O, Stierner U, Törnblom M, Wahlqvist R, Cavallin-Ståhl E. Individualized intensification of treatment based on tumor marker decline in metastatic nonseminomatous germ cell testicular cancer (NSGCT): A report from the Swedish Norwegian Testicular Cancer Group, SWENOTECA. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5015] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5015 Background: From July 1995 to December 2003, 602 adult patients from Sweden and Norway with metastatic testicular NSGCT were included in a population-based multicenter SWENOTECA protocol with strict guidelines for staging, treatment and follow-up. Methods: The basic strategy of this protocol was to individualize treatment according to AFP and β-HCG decline (t1/2). Satisfactory response to treatment was defined as a t½ for AFP ≤ 7 days and/or β-HCG ≤ 3 days. Initial treatment for all patients was 2 courses of standard BEP. Tumor markers were analyzed once a week during treatment. Patients with satisfactory response went on with BEP while patients with unsatisfactory t1/2 received intensified treatment in two steps with addition of ifosfamide (BEP-if/PEI) in step 1. If still unsatisfactory response the treatment was intensified according to step 2 involving high-dose chemotherapy with stem cell rescue. Postchemotherapy surgery was performed according to protocol guidelines. Results: 99,7% (602 of 604) of all patients with metastatic testicular NSGCT in the population were included in the protocol. Median FU was 72 months. 75% of the patients were treated with BEP, median 4 courses, without intensification, 19% according to intensification step 1 and 6% according to intensification step 2. Five year progression free survival (PFS), cancer specific survival (CSS) and overall survival (OS) grouped according to IGCCCG prognostic score are given in the Table below. There was no significant difference in PFS between the good and intermediate risk group. Death due to all causes was 10,1% (n=61) and treatment related deaths were 1,3 % (n=8). Conclusions: Our results, in a population based patient material, with individualized treatment based on tumor marker decline, are highly encouraging in all risk groups, but most notably in the intermediate risk group. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Olofsson
- University Hospital Lund, Lund, Sweden; University of Bergen, Bergen, Norway; Karolinska University Hospital, Stockholm, Sweden; St. Olavs University Hospital, Trondheim, Norway; Sahlgrenska University Hospital, Göteborg, Sweden; Södersjukhuset, Stockholm, Sweden; Aker University Hospital, Oslo, Norway
| | - O. Dahl
- University Hospital Lund, Lund, Sweden; University of Bergen, Bergen, Norway; Karolinska University Hospital, Stockholm, Sweden; St. Olavs University Hospital, Trondheim, Norway; Sahlgrenska University Hospital, Göteborg, Sweden; Södersjukhuset, Stockholm, Sweden; Aker University Hospital, Oslo, Norway
| | - M. Jerkeman
- University Hospital Lund, Lund, Sweden; University of Bergen, Bergen, Norway; Karolinska University Hospital, Stockholm, Sweden; St. Olavs University Hospital, Trondheim, Norway; Sahlgrenska University Hospital, Göteborg, Sweden; Södersjukhuset, Stockholm, Sweden; Aker University Hospital, Oslo, Norway
| | - G. Cohn-Cedermark
- University Hospital Lund, Lund, Sweden; University of Bergen, Bergen, Norway; Karolinska University Hospital, Stockholm, Sweden; St. Olavs University Hospital, Trondheim, Norway; Sahlgrenska University Hospital, Göteborg, Sweden; Södersjukhuset, Stockholm, Sweden; Aker University Hospital, Oslo, Norway
| | - O. Klepp
- University Hospital Lund, Lund, Sweden; University of Bergen, Bergen, Norway; Karolinska University Hospital, Stockholm, Sweden; St. Olavs University Hospital, Trondheim, Norway; Sahlgrenska University Hospital, Göteborg, Sweden; Södersjukhuset, Stockholm, Sweden; Aker University Hospital, Oslo, Norway
| | - U. Stierner
- University Hospital Lund, Lund, Sweden; University of Bergen, Bergen, Norway; Karolinska University Hospital, Stockholm, Sweden; St. Olavs University Hospital, Trondheim, Norway; Sahlgrenska University Hospital, Göteborg, Sweden; Södersjukhuset, Stockholm, Sweden; Aker University Hospital, Oslo, Norway
| | - M. Törnblom
- University Hospital Lund, Lund, Sweden; University of Bergen, Bergen, Norway; Karolinska University Hospital, Stockholm, Sweden; St. Olavs University Hospital, Trondheim, Norway; Sahlgrenska University Hospital, Göteborg, Sweden; Södersjukhuset, Stockholm, Sweden; Aker University Hospital, Oslo, Norway
| | - R. Wahlqvist
- University Hospital Lund, Lund, Sweden; University of Bergen, Bergen, Norway; Karolinska University Hospital, Stockholm, Sweden; St. Olavs University Hospital, Trondheim, Norway; Sahlgrenska University Hospital, Göteborg, Sweden; Södersjukhuset, Stockholm, Sweden; Aker University Hospital, Oslo, Norway
| | - E. Cavallin-Ståhl
- University Hospital Lund, Lund, Sweden; University of Bergen, Bergen, Norway; Karolinska University Hospital, Stockholm, Sweden; St. Olavs University Hospital, Trondheim, Norway; Sahlgrenska University Hospital, Göteborg, Sweden; Södersjukhuset, Stockholm, Sweden; Aker University Hospital, Oslo, Norway
| | | |
Collapse
|
34
|
Jerkeman M, Leppä S, Kvaløy S, Holte H. ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma - the Nordic Lymphoma Group experience. Eur J Haematol 2004; 73:179-82. [PMID: 15287915 DOI: 10.1111/j.1600-0609.2004.00294.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
OBJECTIVE To evaluate ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma, in terms of objective response rate (ORR) and peripheral blood stem cell (PBSC) harvest mobilization rate. PATIENT POPULATION A total of 40 patients were included, with a median age of 57 yr. The major histopathological subgroup was diffuse large B-cell lymphoma (n = 27). The indication for ICE was relapse in 23 patients, primary progressive disease in 11, transformation in four and adjuvant primary chemotherapy in one patient. RESULTS After three cycles of ICE, the ORR was 59%. Among patients with primary progressive disease, ORR was 36% (four of 11). A PBSC harvest after ICE could be performed in 11 of 20 patients, and was sufficient for stem cell rescue in 10 of 20. The median number of collected CD34+ cells was 3.6 x 10(6) (range 1.4-12.5). In six of 10 patients, an adequate PBSC harvest could be performed with a second mobilization regimen. CONCLUSION In this patient population, the rate of response to ICE was comparable with other second-line regimens used in aggressive lymphoma. The rate of harvest failure (45%) was disappointingly high, compared with previous reports, possibly because of patient selection or differences in granulocyte-colony stimulating factor (G-CSF) dosage.
Collapse
Affiliation(s)
- M Jerkeman
- Department of Oncology, Lund University Hospital, Sweden.
| | | | | | | |
Collapse
|
35
|
Jerkeman M, Anderson H, Dictor M, Kvaløy S, Akerman M, Cavallin-Ståhl E. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma?a Nordic Lymphoma Group study. Ann Hematol 2004; 83:414-9. [PMID: 15085385 DOI: 10.1007/s00277-004-0855-x] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2003] [Accepted: 01/25/2004] [Indexed: 11/28/2022]
Abstract
The purpose of this study was to investigate the prognostic effects of four biological markers, BCL2, TP53, Ki-67, and P-glycoprotein, and their possible clinical relevance in addition to the international prognostic index (IPI) in diffuse large B-cell lymphoma (DLBCL). A total of 405 patients with aggressive lymphoma, stage II-IV, between 18 and 67 years, were randomized in a trial comparing CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin). Of these, 267 cases were classified as DLBCL, with adequate paraffin blocks available in 207 cases, enabling immunohistochemical assessment of the expression of BCL2, TP53, P-glycoprotein, and Ki-67. In a multivariate analysis, stratified for IPI, high BCL2 expression (>10%) low (<60%) expression of Ki-67, and high TP53 protein expression (>75%) were shown to provide additional prognostic information with regard to overall or failure-free survival. We found no association between expression of P-glycoprotein and outcome. Assessment of BCL2 positivity might be introduced as part of the routine investigation in patients with DLBCL, but further studies are necessary to confirm the clinical relevance of Ki-67 and TP53 expression.
Collapse
Affiliation(s)
- M Jerkeman
- Department of Oncology, Jubileum Institute, Lund University Hospital, Sweden.
| | | | | | | | | | | |
Collapse
|
36
|
Jerkeman M, Kaasa S, Hjermstad M, Kvaløy S, Cavallin-Stahl E. Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial. Med Oncol 2002; 18:85-94. [PMID: 11778974 DOI: 10.1385/mo:18:1:85] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
This study was conducted to explore treatment and disease-related effects on health-related quality of life (HRQoL) in patients with aggressive lymphoma, to identify predictors for impaired long-term HRQoL, and to analyze the prognostic value of pretreatment HRQoL. Ninety-five patients with aggressive lymphoma, constituting a subset of a randomized multicenter trial comparing CHOP and MACOP-B, entered a HRQoL study, using the EORTC QLQ-C30 questionnaire. Patient scores were compared to scores from an age- and gender-adjusted reference population sample, and evaluation of the prognostic value of pretreatment QoL scores in relation to clinical prognostic factors was performed. Before treatment, patients exhibited lower scores of global QoL, physical, role, and social functions, and more appetite loss, compared to the reference population. Role functioning improved compared to baseline, but remained depressed compared to the reference group more than 8 mo after end of treatment. By then, the patient group displayed no difference in other HRQoL variables compared to that of the reference population. No reliable predictor for impaired long-term HRQoL could be identified. In multivariate analysis, including the factors of the International Prognostic Index, pretreatment global QoL was an independent prognostic marker for overall survival. In conclusion, in this population with aggressive lymphoma and favorable prognostic features, HRQoL was not substantially affected during the first year after diagnosis. Pretreatment global QoL may constitute a significant prognostic factor, meriting further investigation in prospective studies.
Collapse
Affiliation(s)
- M Jerkeman
- Department of Oncology, Lund University Hospital, Lund, Sweden.
| | | | | | | | | |
Collapse
|
37
|
Jerkeman M, Aman P, Cavallin-Stahl E, Torlakovic E, Akerman M, Mitelman F, Fioretos T. Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study. Int J Oncol 2002; 20:161-5. [PMID: 11743658 DOI: 10.3892/ijo.20.1.161] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The purpose of this study was to investigate the prognostic implications of BCL6 rearrangement in a uniformly treated population of patients with diffuse large B-cell lymphoma (DLBCL) and to characterise the relationship between BCL6 rearrangement and prognostic factors. A total of 269 patients with DLBCL entered a randomised trial comparing the chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) to the MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin) regimen. In 44 cases, frozen tissue was available for assessment of BCL6 status by Southern blot analysis. BCL6 was rearranged in six of 43 evaluable cases (14%), and was associated with elevated lactate dehydrogenase (LDH), and a higher patient age. No association between BCL6 status and expression of BCL2, Ki-67 or TP53 was found. Patients presenting with BCL6 rearrangement displayed a weak trend towards better overall and failure-free survival (67 and 67% at 5 years), compared to patients with germline BCL6 (63 and 52%), but the difference was not statistically significant. In accordance with previously published series, the presence of BCL6 rearrangement does not define a prognostically distinct subgroup of DLBCL. Assessment of BCL6 status may, however, be of clinical interest when related to other prognostic variables.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Bleomycin/therapeutic use
- Blotting, Southern
- Cyclophosphamide/therapeutic use
- DNA, Neoplasm/analysis
- DNA, Neoplasm/metabolism
- DNA-Binding Proteins/genetics
- Doxorubicin/therapeutic use
- Gene Rearrangement, B-Lymphocyte/genetics
- Humans
- Immunophenotyping
- L-Lactate Dehydrogenase/metabolism
- Leucovorin/therapeutic use
- Lymphoma, B-Cell/drug therapy
- Lymphoma, B-Cell/genetics
- Lymphoma, Large B-Cell, Diffuse/drug therapy
- Lymphoma, Large B-Cell, Diffuse/genetics
- Male
- Methotrexate/therapeutic use
- Middle Aged
- Neoplasm Staging
- Prednisone/therapeutic use
- Prognosis
- Proto-Oncogene Proteins/genetics
- Proto-Oncogene Proteins c-bcl-6
- Transcription Factors/genetics
- Vincristine/therapeutic use
Collapse
Affiliation(s)
- M Jerkeman
- Department of Oncology, Lund University Hospital, SE-221 85 Lund, Sweden.
| | | | | | | | | | | | | |
Collapse
|
38
|
Rodriguez-Catarino M, Jerkeman M, Ahlström H, Glimelius B, Hagberg H. Residual mass in aggressive lymphoma--does size, measured by computed tomography, influence clinical outcome? Acta Oncol 2001; 39:485-9. [PMID: 11041110 DOI: 10.1080/028418600750013393] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
Residual masses are frequently found in patients with aggressive lymphomas, following therapy. A study was undertaken to determine whether initial tumour size, changes during treatment, or size of the residual mass could provide prognostic information. Computed tomography (CT) examinations were carried out before, midway and after completion of chemotherapy in 37 patients with aggressive lymphoma with residual mass after treatment. The tumours were measured for both the greatest diameter sizes and area. The size of the residual mass correlated with the tumour size at diagnosis. Neither a large tumour size before treatment nor a large residual mass after treatment correlated with an increase in rate of relapse. The initial tumour reduction (measured after completion of half of the planned chemotherapy) was less pronounced in relapsing patients compared to relapse-free patients. Using a cut-off level of 70% tumour reduction (measured after completion of half of the planned chemotherapy), 66% of patients with a tumour reduction of < 70% relapsed, compared with 22% (p < 0.05) in those with more marked tumour regression.
Collapse
Affiliation(s)
- M Rodriguez-Catarino
- Department of Oncology, Radiology and Clinical Immunology, Akademiska Sjukhuset, University of Uppsala, Sweden.
| | | | | | | | | |
Collapse
|
39
|
Messori A, Vaiani M, Trippoli S, Rigacci L, Jerkeman M, Longo G. Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP. Br J Cancer 2001; 84:303-7. [PMID: 11161392 PMCID: PMC2363752 DOI: 10.1054/bjoc.2000.1566] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
In patients with intermediate or high grade non-Hodgkin lymphoma (NHL), third generation chemotherapy regimens have been introduced to improve survival in comparison with the standard CHOP regimen. However, most studies have found no difference between these two treatments. We conducted a meta-analysis to assess the effectiveness of third generation regimens as compared with CHOP. Our study included the randomized controlled trials published in English from 1970 to 1999. After a Medline search, 5 trials were found to meet our inclusion criteria. A total of 1982 patients, that were enrolled in these trials, were included in the survival meta-analysis. Our methodology retrieved patient-level information from all of these subjects; survival up to 9 years after randomization was compared between the two treatment options. The results of our meta-analysis showed that, in comparison with CHOP, third generation chemotherapy did not prolong survival at levels of statistical significance (chi-square by log-rank test = 1.44, P = 0.23). The relative death risk for third generation regimens vs. CHOP was 0.92 (95%CI: 0.80 to 1.06;P = 0.26). We conclude that, on the basis of our meta-analysis, third generation regimens do not confer any survival benefit to patients with intermediate or high grade NHL as compared with CHOP.
Collapse
Affiliation(s)
- A Messori
- Drug Information Center Azienda Ospedaliera Careggi, Firenze, Italy
| | | | | | | | | | | |
Collapse
|
40
|
Jerkeman M, Anderson H, Cavallin-Ståhl E, Dictor M, Hagberg H, Johnson A, Kaasa S, Kvaløy S, Sundström C, Akerman M. CHOP versus MACOP-B in aggressive lymphoma--a Nordic Lymphoma Group randomised trial. Ann Oncol 1999; 10:1079-86. [PMID: 10572606 DOI: 10.1023/a:1008392528248] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The long-term survival of patients with advanced stage aggressive lymphoma has not improved significantly during the last twenty years. In a randomised trial, the efficacy of MACOP-B, a six-drug weekly chemotherapy regimen, was compared to CHOP, the current standard regimen, in terms of overall and failure-free survival, toxicity and health related quality of life. PATIENTS AND METHODS Four hundred five patients with aggressive lymphoma, stage II-IV, age 18-67, were randomised to receive either 12 weeks of MACOP-B or 8 courses of CHOP over 24 weeks. Special emphasis was put in the definition of Ann Arbor stage in extranodal disease. A subset of 95 patients also entered a quality of life study, based on the EORTC QLQ-C30. RESULTS Thirty-one patients were ineligible. Among the remaining 374 patients, the median age was 52 years. According to the age-adjusted International Prognostic Index, 37% were 'high-intermediate' or 'high-risk' patients. No difference could be demonstrated, either in overall survival (60% at five years in the MACOP-B group and 59% in the CHOP group) or in failure-free survival (47% at five years with MACOP-B and 44% with CHOP). In terms of quality of life, physical function and global quality of life were more impaired in patients receiving MACOP-B, who also exhibited more non-haematological toxicity. CONCLUSION No superiority of MACOP-B compared to CHOP could be demonstrated. CHOP remains the treatment of choice in low-risk patients. At present, intensified or experimental treatment should be reserved for high-risk disease.
Collapse
Affiliation(s)
- M Jerkeman
- Department of Oncology, Jubileum Institute, Lund University Hospital, Sweden.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Jerkeman M, Johansson B, Akerman M, Cavallin-Ståhl E, Kristoffersson U, Mitelman F. Prognostic implications of cytogenetic aberrations in diffuse large B-cell lymphomas. Eur J Haematol 1999; 62:184-90. [PMID: 10089896 DOI: 10.1111/j.1600-0609.1999.tb01742.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A single institution series of 81 consecutive, cytogenetically analyzed, diffuse large B-cell lymphomas (DLBL), the majority of which treated with anthracycline-containing combination chemotherapy, were reviewed retrospectively to investigate whether the karyotypic pattern or certain abnormalities correlate with survival. Clonal chromosome changes were found in 79 of the 81 cases. The prognostic impact of the following aberrations, all suggested in previous studies to be associated with either shorter or longer survival, were tested: 1q21-23 breakpoints, +2/dup(2p), +3/dup(3p), +5, +6, 6q21-25 breakpoints, monosomy 7/der(7p)/i(7q), trisomy 7, 14q11-12 breakpoints, monosomy 17/der(17p)/i(17q), trisomy 18, > 4 marker chromosomes, > 4 breakpoints, and > or = 10 abnormalities. Univariate analysis showed that a breakpoint at 1q21-23 or trisomy 6 was associated with a shorter survival. However, when adjusted for age, stage, performance status and lactate dehydrogenase level, none of the cytogenetic aberrations had an independent prognostic value. Thus, the present investigation provides no support for any of the above-mentioned abnormalities being of prognostic importance in DLBL.
Collapse
Affiliation(s)
- M Jerkeman
- Department of Oncology, University Hospital, Lund, Sweden.
| | | | | | | | | | | |
Collapse
|
42
|
Abstract
Patients with febrile urinary tract infections with (80 patients) or without (88 patients) positive blood cultures were reviewed. Eighty-nine percent of the infections were community acquired. The bacteremic patients were older, Escherichia coli was the most commonly found organism in both groups. The most important finding in this study was increased frequency of resistance to three common urinary tract antibiotics (ampicillin, cephalothin and trimethoprim-sulfamethoxazole) in E. coli from patients with non-bacteremic compared with bacteremic infections. Complications occurred in 28 bacteremic and in three non-bacteremic patients. Six patients died, all with bacteremia. The significantly higher temperature at admittance among patients with gram-negative versus gram-positive bacteremic infection possibly reflects an effect by endotoxin.
Collapse
Affiliation(s)
- M Jerkeman
- Dept. of Infectious Diseases, University Hospital, Lund, Sweden
| | | |
Collapse
|